Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Regeneron's (REGN) Q2 revenue jumped 17% to $4.3 billion, and the driver was Dupixent, not Eylea. Dupixent collaboration revenue surged 51%, even as Eylea sales continue to decline.

Dupixent, developed with Sanofi (SNY), generated $6 billion in global sales, up 38% year over year. The gap between Dupixent's 51% collaboration revenue growth and the company's 17% total revenue growth shows how much the profit share is carrying the top line. Interpretation: the Eylea decline is being absorbed by a single partnered franchise, which concentrates REGN's earnings exposure in Dupixent.

The long-term risk is explicit. Dupixent faces biosimilar competition in the early 2030s. Regeneron's stated defense has three parts: improved formulations, pipeline replacements, and candidates such as olatorepatide in the weight-loss market. None of those has produced revenue yet, so the replacement story remains a forward-looking thesis rather than a reported number.

For SNY, the same 38% Dupixent growth underpins the partnership economics, though the source focuses on Regeneron's share of the profits.